What is the physiology of cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2)?

Answer

Evidence suggests that COX-1 and COX-2 are similar in structure and function but that they exist as 2 distinct enzymatic entities. They have been defined as monotropic integral membrane proteins located primarily in the endoplasmic reticulum (COX-1) and the perinuclear envelope (COX-2). Their distinct biosynthetic activity includes an endoperoxidase synthase reaction that oxygenates and cyclizes polyunsaturated fatty acid precursors (eg, arachidonic acid) to form prostaglandin G₂ (PGG2), and a peroxidase reaction that converts PGG2 to prostaglandin H₂ (PGH2), as shown below. In turn, PGH2 is converted to biologically active products (ie, prostaglandin E₂ [PGE2]) by individual synthase and reductase reactions.

Cyclooxygenase conversion of arachidonic acid into prostaglandin H2 (PGH2).

View Media Gallery

COX-1 is expressed constitutively and is isolated throughout most cell lines in almost all mammalian tissues. It is described as a housekeeping enzyme, being responsible for cell-to-cell signaling, tissue homeostasis, and cytoprotection. In view of this, researchers hypothesize that COX-1 is a rapid responder to various physiologic conditions.

Conversely, COX-2 is described as an inducible isoform influenced by a plethora of proinflammatory mediators. Without appropriate stimulation, isolation of the COX-2 protein is negligible in most tissues. However, newer literature reveals that COX-2 is expressed constitutively in some cell lines of the brain, kidney, and trachea. Although vaguely described, COX-2 is considered to be a principal mediator of inflammation, mitogenesis, and angiogenesis.

Studies have demonstrated that the eicosanoids produced by cytosolic COX-1 participate in autocrine and paracrine activities, while those produced by perinuclear COX-2 result in intracrine activity. This subcellular localization of the COX enzyme (through the use of new microscopy techniques) has helped to explain why 2 isoforms exist. Furthermore, researchers have proposed that COX-1 and COX-2 acquire arachidonic acid from different phospholipases, suggesting participation through separate pathways.

Did this answer your question?

Yes No

Additional feedback? (Optional)

Thank you for your feedback!

Khanapure SP, Garvey DS, Janero DR, et al. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem. 2007. 7(3):311-40. [Medline].
Nyman D, Eriksson AW, Blomback M, et al. Recent investigations of the first bleeder family in Aland (Finland) described by von Willebrand. Thromb Haemost. 1981 Feb 23. 45(1):73-6. [Medline].
Nyman D, Eriksson AW, Lehmann W, et al. Inherited defective platelet aggregation with arachidonate as the main expression of a defective metabolism of arachidonic acid. Thromb Res. 1979. 14(4-5):739-46. [Medline].
Horellou MH, Lecompte T, Lecrubier C, et al. Familial and constitutional bleeding disorder due to platelet cyclo-oxygenase deficiency. Am J Hematol. 1983 Feb. 14(1):1-9. [Medline].
Nasrallah R, Clark J, Hebert RL. Prostaglandins in the kidney: developments since Y2K. Clin Sci (Lond). 2007 Oct. 113(7):297-311. [Medline].
Langenbach R, Loftin C, Lee C, et al. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol. 1999 Oct 15. 58(8):1237-46. [Medline].
Lim H, Paria BC, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell. 1997 Oct 17. 91(2):197-208. [Medline].
Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995 Nov 23. 378(6555):406-9. [Medline].
Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest. 1999 Apr. 103(7):953-61. [Medline]. [Full Text].
Pidgeon GP, Lysaght J, Krishnamoorthy S, et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 2007 Dec. 26(3-4):503-24. [Medline].
Sasaki Y, Ochiai T, Takamura M, Kondo Y, Yokoyama C, Hara S. Role of prostacyclin synthase in carcinogenesis. Prostaglandins Other Lipid Mediat. 2017 Nov. 133:49-52. [Medline].
Huang QC, Huang RY. The cyclooxygenase-2/thromboxane A2 pathway: a bridge from rheumatoid arthritis to lung cancer?. Cancer Lett. 2014 Nov 1. 354 (1):28-32. [Medline].
Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007 Dec. 26(3-4):525-34. [Medline].
Xie C, Xu X, Wang X, Wei S, Shao L, Chen J, et al. Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E₂. Oncol Lett. 2018 Jul. 16 (1):940-948. [Medline].
Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2007 Mar. 23(2):134-41. [Medline].
Coceani F, Barogi S, Brizzi F, et al. Cyclooxygenase isoenzymes and patency of ductus arteriosus. Prostaglandins Leukot Essent Fatty Acids. 2005 Feb. 72(2):71-7. [Medline].
Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford). 2005 Jul. 44(7):846-59. [Medline]. [Full Text].
Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999 May 31. 106(5B):25S-36S. [Medline].
Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract. 2007 May. 61(5):826-34. [Medline].
Patrono C, Rocca B. Drug insight: aspirin resistance--fact or fashion?. Nat Clin Pract Cardiovasc Med. 2007 Jan. 4(1):42-50. [Medline].
Ludwig HC, Birdwhistell KE, Brainard BM, Franklin SP. Use of a Cyclooxygenase-2 Inhibitor Does Not Inhibit Platelet Activation or Growth Factor Release From Platelet-Rich Plasma. Am J Sports Med. 2017 Dec. 45 (14):3351-3357. [Medline].
Rolf N, Knoefler R, Bugert P, et al. Clinical and laboratory phenotypes associated with the aspirin-like defect: a study in 17 unrelated families. Br J Haematol. 2009 Feb. 144(3):416-24. [Medline].
Boutaud O, Sosa IR, Amin T, Oram D, Adler D, Hwang HS, et al. Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila). 2016 Nov. 9 (11):855-865. [Medline]. [Full Text].
Prieto P, Jaén RI, Calle D, Gómez-Serrano M, Núñez E, Fernández-Velasco M, et al. Interplay between post-translational cyclooxygenase-2 modifications and the metabolic and proteomic profile in a colorectal cancer cohort. World J Gastroenterol. 2019 Jan 28. 25 (4):433-446. [Medline].
Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995 Nov 3. 83(3):493-501. [Medline].
Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996 Nov 29. 87(5):803-9. [Medline].
Oshima M, Oshima H, Tsutsumi M, et al. Effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine on intestinal polyp development in Apc delta 716 knockout mice. Mol Carcinog. 1996 Jan. 15(1):11-7. [Medline].
Sanborn R, Blanke CD. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?. Semin Oncol. 2005 Feb. 32(1):69-75. [Medline].
Rajput S, Wilber A. Roles of inflammation in cancer initiation, progression, and metastasis. Front Biosci (Schol Ed). 2010 Jan 1. 2:176-83. [Medline].
Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11. 373(9671):1301-9. [Medline].
Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005 Apr 20. 23(12):2840-55. [Medline].
Ahmetaj-Shala B, Tesfai A, Constantinou C, Leszczynski R, Chan MV, Gashaw H, et al. Pharmacological assessment of ibuprofen arginate on platelet aggregation and colon cancer cell killing. Biochem Biophys Res Commun. 2017 Mar 18. 484 (4):762-766. [Medline].
Zhang DQ, Guo Q, Zhu JH, Chen WC. Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World J Surg Oncol. 2013. 11:16. [Medline].
Hersh EV, Lally ET, Moore PA. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?. Curr Med Res Opin. 2005 Aug. 21(8):1217-26. [Medline].
Sohn HY, Krötz F. Cyclooxygenase inhibition and atherothrombosis. Curr Drug Targets. 2006 Oct. 7(10):1275-84. [Medline].
Straube S, Derry S, McQuay HJ, et al. Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies. Acta Anaesthesiol Scand. 2005 May. 49(5):601-13. [Medline].
Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995 May. 15(3):179-94. [Medline].
Botting RM. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep. 2010 May-Jun. 62(3):518-25. [Medline].
Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol. 1996. 62:167-215. [Medline].
Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol. 2006 Nov. 57 Suppl 5:113-24. [Medline]. [Full Text].
Setia S, Vaish V, Sanyal SN. Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis. Mol Cell Biochem. 2012 Jul. 366 (1-2):89-99. [Medline].

Media Gallery

Twenty-carbon polyunsaturated fatty acid with cyclopentane ring.
Cyclooxygenase conversion of arachidonic acid into prostaglandin H2 (PGH2).
Thromboxane A2 (TXA2).
Prostacyclin (PGI2).
Prostaglandin E2 (PGE2).

of 5

What is the physiology of cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2)?

Answer

Related Questions:

References

Tables

Contributor Information and Disclosures